Close
Close
People News

Sangamo Therapeutics Announces Technology Leadership Changes

2.75
2.8 from 4 votes
Monday, July 16, 2018

RICHMOND, CA - Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced that Michael Holmes, Ph.D., Senior Vice President and Chief Technology Officer, will resign from the Company effective July 20th to pursue an opportunity with a startup biotech company. Edward Rebar, Ph.D., has been named Senior Vice President and Chief Technology Officer, effective immediately.

"We wish Michael well in his new endeavor," said Sandy Macrae, CEO of Sangamo. "We are grateful for his contributions to Sangamo over the years and are excited for him as he pursues this ground-floor opportunity at a biotech startup."

Dr. Holmes joined Sangamo in 2001 as a senior scientist and over the years has been promoted to lead many of Sangamo's research programs. Along with Dr. Rebar and other Sangamo scientists, Dr. Holmes made important contributions to the development of zinc finger proteins for therapeutic, research and agricultural applications. He was named Chief Technology Officer earlier in 2018.

Dr. Rebar joined Sangamo in 1998, and over the last 20 years he has led the development of the Company's zinc finger protein platform. He has authored over 60 publications relating to the development of customized DNA binding proteins and nucleases for genome editing. Prior to joining Sangamo, he was a post-doctoral fellow at the University of California, Berkeley. Dr. Rebar earned his B.S. in Biochemistry from Rutgers University and his Ph.D. in Biophysics and Structural Biology from MIT.

"I'm very pleased to announce Ed Rebar's promotion to Chief Technology Officer," Macrae said. "During his tenure at Sangamo, Ed has led the development and optimization of our core zinc finger technology. In the field of genome editing he is recognized as a leader and a strong voice for setting very high standards for editing technology being developed for therapeutic use."

About Sangamo Therapeutics
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. For more information about Sangamo, visit the Company's website at www.sangamo.com.

Contact:
Investor Relations
McDavid Stilwell
Corporate Communications
T: 510-970-6000 x219
F: 510-236-8951
investor@sangamo.com

Source: Sangamo Therapeutics, Inc.
2.75
2.8 from 4 votes
Free Newsletter
Trending News